1. ALLA AKTIER
  2. NYHETER
  3. VITROLIFE

Vitrolife

Nyheter Vitrolife Nyheter alla bolag

Interim report Q1, 2025: Strong performance in EMEA

REG

First quarter 

  • Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. 
  • Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. 
  • Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. 
  • Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. 
  • Gross margin increased to 57.4% (57.1). 
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. 
  • Operating cash flow amounted to SEK 69 million (198). 
  • Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).


Gothenburg, April 24, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
 

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET.

Datum 2025-04-24, kl 08:00
Källa Cision
Bifogade filer
Interim report Q1, 2025
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!